Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
In a recently completed Phase 3, double-blind, randomized, controlled trial of once-weekly tirzepatide in the treatment of obesity, tirzepatide 15 mg achieved a mean percentage change in body weight of -20.9% (-21.9 kg) over 72 weeks of treatment, suggesting that tirzepatide 15 mg is also a potential weight loss agent ( Semaglutide1.0mg and oral semaglutide 14mg was inferior to tirzepatide in reducing HbA1c and body weight but had significant advantages over other GLP-1RAs
The additional activation of the GIP receptor is hypothesised to enhance insulin sensitivity and may contribute to improved tolerability of the GLP-1 component, though this remains under investigation and has not been definitively demonstrated for retatrutide specifically
And track how your body reacts after each shot
Approximately 15.2% of participants receiving the drug experienced headaches, compared with 12.2% of those receiving a placebo (a treatment with no active medication)
Consult a Professional Before you initiate CJC-1295/Ipamorelin or any peptide therapy, its very important to consult a qualified health care provider
